Patents by Inventor Filomena Nappi

Filomena Nappi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel post-transcriptional regulatory elements and uses thereof
    Publication number: 20060188872
    Abstract: The invention provides a novel post-transcriptional regulatory element that can function as an RNA nucleo-cytoplasmic transport element. The invention also provides for an attenuated HIV-1 hybrid virus for use as a vaccine and a kit incorporating the hybrid virus. The kit also includes instructional material teaching the use of the vaccine, where the instructional material indicates that the vaccine is used for the prophylaxis or amelioration of HIV-1 infection in a mammal; that the vaccine is to be administered to a mammal in a therapeutically effective amount sufficient to express a viral protein; where the vaccine will not cause clinically significant CD4+ cell depletion; and, the expression of the viral protein elicits an immune response to the attenuated HIV-1 virus. The invention further provides for a method for screening for post-transcriptional RNA nucleo-cytoplasmic transport element (NCTE) binding proteins.
    Type: Application
    Filed: May 16, 2005
    Publication date: August 24, 2006
    Applicant: The Gov. of the USA as Represented by the Secretary Dept. of Health and Human Services
    Inventors: George Pavlakis, Filomena Nappi
  • Nucleic acids comprising a post-transcriptional regulatory element (PRE) and their uses
    Patent number: 6919442
    Abstract: The invention provides a novel post-transcriptional regulatory element that can function as an RNA nucleo-cytoplasmic transport element. The invention also provides for an attenuated HIV-1 hybrid virus for use as a vaccine and a kit incorporating the hybrid virus. The kit also includes instructional material teaching the use of the vaccine, where the instructional material indicates that the vaccine is used for the prophylaxis or amelioration of HIV-1 infection in a mammal; that the vaccine is to be administered to a mammal in a therapeutically effective amount sufficient to express a viral protein; where the vaccine will not cause clinically significant CD4+ cell depletion; and, the expression of the viral protein elicits an immune response to the attenuated HIV-1 virus. The invention further provides for a method for screening for post-transcriptional RNA nucleo-cytoplasmic transport element (NCTE) binding proteins.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: July 19, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: George N. Pavlakis, Filomena Nappi